Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upPaolo G. Casali, Martin Robinson, Michael Montemurro et al.|Annals of Oncology|2018Cited by 1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D. Demetri, Paolo G. Casali, Peter Reichardt et al.|The Lancet|2012Cited by 1.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆Alessandro Gronchi, Silvia Stacchiotti, Javier Martín‐Broto et al.|Annals of Oncology|2021Cited by 978
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialPatrick Schöffski, Shreyaskumar Patel, Sant P. Chawla et al.|The Lancet|2016Cited by 766
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upPaolo G. Casali, Jean‐Yves Blay, Martin Robinson et al.|Annals of Oncology|2018Cited by 751